News | Congenital Heart | May 01, 2021

Global registry Shows Longer Stent Minimizes Procedure Complications in Sinus Venosus Atrial Septal Defects

Technology provides procedure efficiencies for congenital heart disease patients

The NuMED 10-zig Covered CP (CCP) balloon expandable covered stent. It is used for repair of sinus venosus atrial septal defects (SVASD). #SVASD #SCAI2021 #congenitalheart #

The NuMED 10-zig Covered CP (CCP) balloon expandable covered stent.


May 1, 2021 - An analysis of a new international registry reveals benefits of using a longer covered stent for interventional procedures in congenital heart disease patients with sinus venosus atrial septal defect (SVASD). The study was presented this week as late-breaking clinical research at the Society of Cardiovascular Angiography and Interventions (SCAI) 2021 Scientific Sessions.

SVASD is a rare adult congenital heart disease that permits shunting of blood from the systemic to the pulmonary circulation , causing excessive blood flow to the lungs. Until now, open heart surgical repair was the gold standard approach to dealing with this condition but is necessarily invasive. Covered stent implantation is a recently developed interventional procedure that can replace open heart surgery in some of these patients. However, according to the study authors, there is no "ideal stent" often leaving physicians to modify existing stents and frequently needing to "piggy back" several stents which adds to the difficulty and potential complications of the procedure.

Investigators analyzed outcomes of the NuMED 10-zig Covered CP (CCP) Stent, which is balloon expandable and intended for permanent implant in patients. It is composed of 0.013" platinum-iridium wire arranged in a 10 zig pattern that is laser welded at each joint and then over brazed with 24K gold. The 10-zig CCP stent was implanted in 75 patients between the ages of 11-75 years (median 45) from 12 centers. Pre-procedural assessment included diagnostic catheterization in 30, 3-D printed models in 34 and virtual models in 13.

Results showed 10-zig CCPs of 7-8 cm provided reliable SVASD closure with a low requirement for additional stents. An additional stent was placed in 4/5 (80%) with 5/5.5 cm CCPs, 18/29 (62%) with 6 cm CCPs, 5/18 (28%) with 7 cm CCPs, 5/22 (23%) with 7.5/8 cm CCPs and 0/1 with an 11 cm CCP. Patients were followed from three weeks to five years.

"Our findings reveal that the novel, longer stents are a reliable advance in technology that significantly reduces the need for implantation of additional stents. This helps to minimize many of the procedural risk factors and enhances the outcome. More SVASD patients will become eligible to undergo this novel interventional procedure and they will therefore avoid the need for open-heart surgery," said Prof Eric Rosenthal, M.D., lead study investigator and pediatric and adult congenital cardiologist at Guy's and St. Thomas NHS Foundation Trust in London, England. "These encouraging results support the need for further research into the long-term benefits of the 10-zig stents while widening its use in patients with SVASD."

Authors note that the longer covered stents are still investigational and require regulatory clearance at most centers.

 

Find more news from the SCAI 2021 virtual meeting

Find more congenital heart technology news

 


Related Content

News | Cardiovascular Clinical Studies

September 8, 2022 — A clinical trial led by investigators from Brigham and Women’s Hospital has found that the long-term ...

Home September 08, 2022
Home
News | Cardiovascular Clinical Studies

August 17, 2022 — A study carried out by scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) ...

Home August 17, 2022
Home
News | Cardiovascular Clinical Studies

August 12, 2022 — Older adults with atrial cardiopathy (a major, often undetected cardiac cause of stroke) may be at ...

Home August 12, 2022
Home
News | Cardiovascular Clinical Studies

August 8, 2022 — Two years ago, University of Alabama at Birmingham researchers and colleagues reported that reductive ...

Home August 08, 2022
Home
News | Cardiovascular Clinical Studies

July 22, 2022 — BioSig Technologies, Inc. a medical technology company advancing electrophysiology workflow by ...

Home July 22, 2022
Home
News | Cardiovascular Clinical Studies

July 18, 2022 — scPharmaceuticals Inc., a pharmaceutical company focused on developing and commercializing products that ...

Home July 19, 2022
Home
News | Cardiovascular Clinical Studies

July 15, 2022 — Imagine, if scientists had a map of the heart, so granular in its accuracy that it even profiled details ...

Home July 15, 2022
Home
News | Cardiovascular Clinical Studies

July 11, 2022 — Smoking traditional or non-combustible cigarettes while wearing a surgical mask results in a two-fold ...

Home July 12, 2022
Home
News | Cardiovascular Clinical Studies

June 24, 2022 — Henry Ford Health was part of a multi-institutional heart failure study that was launched and executed ...

Home June 24, 2022
Home
News | Cardiovascular Clinical Studies

June 21, 2022 — Renibus Therapeutics (“Renibus”), a clinical-stage biotech company focusing on the prevention and ...

Home June 21, 2022
Home
Subscribe Now